wire - news in brief

« BACK

Life Sciences



Results 1 - 50 of 537.
1 2 3 4 5 ... 11 Next »

Environment/Sustainable Development - Life Sciences
20.03.2017
ACE completes its voyage around Antarctica
The Antarctic Circumnavigation Expedition (ACE) reached Cape Town on Sunday, 19 March, completing its three-month voyage around the great white continent. But the scientific adventure has only just begun: it's now time to analyze all the data that was collected. This will improve our understanding of the effects of global warming on the Southern Ocean and the broader implications for our planet as a whole.
Life Sciences - Medicine/Pharmacology
17.03.2017
Cut the long story short - and stitch it back together
Cut the long story short - and stitch it back together
Media releases, information for representatives of the media Media Relations (E) A species of unicellular ciliate has found a special trick to make use of the cellular machinery in seemingly impossible ways.
Life Sciences - Environment/Sustainable Development
14.03.2017
Spiders Eat 400-800 Million Tons of Prey Every Year
Spiders Eat 400-800 Million Tons of Prey Every Year
It has long been suspected that spiders are one of the most important groups of predators of insects.
Medicine/Pharmacology - Life Sciences
13.03.2017
Novartis Kisqali (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
Novartis Kisqali (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor Approved based on a first-line P
Medicine/Pharmacology - Life Sciences
13.03.2017
Joint Efforts Towards Treating Paralysis
EPFL scientists Stéphanie Lacour and Grégoire Courtine report on the status of their research and share their vision about the future of wearable neuroprosthetics at this year's edition of South by South West in Austin, Texas, on March 12 th .
Life Sciences - Physics/Materials Science
10.03.2017
New professors appointed
New professors appointed
The ETH Board appointed three new professors and awarded the title of Professor to five recipients upon application of ETH President Lino Guzzella At its meeting of 8/9 March 2017, the ETH Board appo
Medicine/Pharmacology - Life Sciences
06.03.2017
New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine
Sandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira * Comprehensive development program show potential of GP2017 to treat inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis Study reinforces strength of Sandoz pipeline and its key role in the broader Novartis immunology portfolio Holzkirchen, 6 March 2017 - Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today presented data for its proposed biosimilar adalimumab (GP2017).
Life Sciences - Chemistry
01.03.2017
Researchers Imitate Molecular Crowding in Cells
Researchers Imitate Molecular Crowding in Cells
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Life Sciences - Medicine/Pharmacology
28.02.2017
Stem cells derived neuronal networks grown on a chip as an alternative to animal testing
Stem cells derived neuronal networks grown on a chip as an alternative to animal testing
Media releases, information for representatives of the media Media Relations (E) Scientists at the Institute for Infectious Diseases, University of Bern have developed an in vitro stem cell-based bio
Medicine/Pharmacology - Life Sciences
24.02.2017
Novartis receives positive CHMP opinion for Tafinlar + Mekinist in BRAF-positive non-small cell lung cancer (NSCLC) patients
If approved, Tafinlar + Mekinist will be the first targeted therapy specifically for NSCLC patients with a BRAF V600 mutation CHMP opinion based on positive data from pivotal study of patients with B
Medicine/Pharmacology - Life Sciences
23.02.2017
Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC
Priority Review based on Phase III study results showing 16.6 month median progression-free survival in previously untreated ALK+ metastatic NSCLC patients on Zykadia vs.
Medicine/Pharmacology - Life Sciences
18.02.2017
Phase II study supports potential for Roche’s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma
Phase II study supports potential for Roche's TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma Proof of concept study in first line mRCC (a type of kidney cancer) shows that TECENTRIQ and Avastin can be combined with a manageable safety profile Study results also showed encouraging efficacy compared to sunitinib in those people whose disease expressed the PD-L1 (programmed de
Computer Science/Telecom - Life Sciences
17.02.2017
Six-Legged Robots Faster Than Nature-Inspired Gait
Six-Legged Robots Faster Than Nature-Inspired Gait
Researchers at EPFL and UNIL have discovered a faster and more efficient gait, never observed in nature, for six-legged robots walking on flat ground. Bio-inspired gaits - less efficient for robots - are used by real insects since they have adhesive pads to walk in three dimensions. The results provide novel approaches for roboticists and new information to biologists.
Chemistry - Life Sciences
07.02.2017
Tiny organisms with a massive impact
Tiny organisms with a massive impact
Although diatoms are incredibly small, they have a significant impact on the dispersal of nutrients and trace elements in global marine waters. This is the conclusion of a study recently published in the scientific journal - Nature Geoscience '. Diatoms are a very common group of algae found not only in freshwater streams, rivers and lakes, but also in marine waters.
Life Sciences - Social Sciences
06.02.2017
Psychotherapy normalizes the brain in social phobia
Anxiety in social situations is not a rare problem: Around one in ten people are affected by social anxiety disorder during their lifetime. Social anxiety disorder is diagnosed if fears and anxiety in social situations significantly impair everyday life and cause intense suffering. Talking in front of a larger group can be one typical feared situation.
Business/Economics - Life Sciences
31.01.2017
In cold water
In cold water
Martin Ostermaier wanted to break out of the comfort zone of science. Now, instead of pipettes, the biochemist is dealing with investors and patent law.
Medicine/Pharmacology - Life Sciences
31.01.2017
Novartis drug Votubia receives EU approval to treat refractory partial-onset seizures in patients with TSC
Votubia is the first adjunctive treatment approved in the EU specifically for partial-onset seizures in children and adults with tuberous sclerosis complex (TSC)   Approval addresses unmet need as up
Life Sciences - Business/Economics
30.01.2017
The Attraction Effect: how our Brains Can Be Influenced
The Attraction Effect: how our Brains Can Be Influenced
The decisions we make are influenced by other possibilities that we did not choose. At the same time, the options we missed out on determine our satisfaction with the outcomes of situations we were unable to control. Psychologists from the University of Basel conducted two experiments: first, they studied the decision-making behavior of students and, second, they measured brain activity and satisfaction when a set of possibilities is supplemented with another alternative.
Medicine/Pharmacology - Life Sciences
27.01.2017
Spin-off Cellestia Biotech raises CHF 8 million in seed financing
Spin-off Cellestia Biotech raises CHF 8 million in seed financing
Cellestia Biotech, an EPFL spin-off, can now carry out clinical trials on its new cancer treatment after raising CHF 8 million in seed money.
Life Sciences - Medicine/Pharmacology
26.01.2017
LSD alters perception via serotonin receptors
Humans perceive everyday things and experiences differently and attach different meaning to pieces of music, for instance. In the case of psychiatric disorders, this perception is often altered. For patients suffering from addictions, for instance, drug stimuli are more meaningful than for people without an addiction.
Life Sciences - Medicine/Pharmacology
23.01.2017
Immune Defense Without Collateral Damage
Immune Defense Without Collateral Damage
Researchers from the University of Basel in Switzerland have clarified the role of the enzyme MPO. In fighting infections, this enzyme, which gives pus its greenish color, produces a highly aggressive acid that can kill pathogens without damaging the surrounding tissue. In the human body's fight against bacterial pathogens, white blood cells are in the front line.
Life Sciences - Medicine/Pharmacology
20.01.2017
Cell fate regulation by LIN41: activity determined by binding location
Helge Großhans and his group at the Friedrich Miescher Institute for Biomedical Research (FMI) have elucidated the mode of action of the RNA-binding protein and stem cell factor LIN41. In an animal model, they showed that LIN41 silences four specific mRNAs, by two distinct mechanisms. They found that the choice of mechanism is determined by where on the mRNA LIN41 binds.
Medicine/Pharmacology - Life Sciences
17.01.2017
On track to heal leukaemia
On track to heal leukaemia
Media releases, information for representatives of the media Media Relations (E) The first clinical studies for a new type of immunotherapy for leukaemia are beginning at Bern's University Hospital and the Department of Clinical Research (DCR) of the University of Bern. Antibodies discovered in the laboratory should inhibit the growth of tumour cells.
Medicine/Pharmacology - Life Sciences
16.01.2017
Every Meal Triggers Inflammation
When we eat, we do not just take in nutrients - we also consume a significant quantity of bacteria. The body is faced with the challenge of simultaneously distributing the ingested glucose and fighting these bacteria.
Medicine/Pharmacology - Life Sciences
09.01.2017
New insights into mechanisms of breast cancer development and resistance to therapy
Why does breast cancer develop and how come certain patients are resistant to established therapies' Researchers from the University of Basel have gained new insights into the molecular processes in breast tissue. They identified the tumor suppressor LATS as a key player in the development and treatment of breast cancer.
Life Sciences - Medicine/Pharmacology
06.01.2017
Medicine/Pharmacology - Life Sciences
06.01.2017
Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders
Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with elevated
Life Sciences - Medicine/Pharmacology
06.01.2017
Autoimmunity and Infections: When the Body Fights Itself
Basel-based doctors are on the trail of a possible connection between autoimmune diseases and infections: errors can occur when immune cells absorb certain proteins from pathogen cells. These It is already known that there is a connection between infections and autoimmunity – the inability of an organism to recognize parts of its own body as “self”.
Life Sciences - Medicine/Pharmacology
27.12.2016
Looking back at 2016 (1/2)
Looking back at 2016 (1/2)
Health, energy, maths and chocolate: no field of research has been neglected last year by EPFL's scientists.  Cheaper solar cells with 20.2% efficiency Some of the most promising solar cells today use light-harvesting films made from perovskites. However, perovskite-based solar cells use expensive ‘hole-transporting' materials, whose function is to move the positive charges that are generated when light hits the perovskite film.
Medicine/Pharmacology - Life Sciences
23.12.2016
Treating cancer with drugs for diabetes and hypertension
Treating cancer with drugs for diabetes and hypertension
A combination of a diabetes medication and an antihypertensive drug can effectively combat cancer cells. The team of researchers led by Prof. Michael Hall at the Biozentrum of the University of Basel has also reported that specific cancer cells respond to this combination of drugs. The results of the study have now been published in ‘Science Advances'.
Medicine/Pharmacology - Life Sciences
21.12.2016
Positive Phase III results for Roche’s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine
Positive Phase III results for Roche's investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine OCREVUS is the first and only investigational medicine to show superior efficacy versus comparators in both relapsing and primary progressive multiple sclerosis in clinical studies OCREVUS demonstrated a favourable safety profile in three large Phase III studies Roche announced today that data from three Phase III st
Environment/Sustainable Development - Life Sciences
20.12.2016
University of Zurich to become global center for biodiversity research
University of Zurich to become global center for biodiversity research
Prof. Michael Schaepman, PhD Department of Geography University of Zurich Phone +41 44 635 51 60 E-mail Prof. Bernhard Schmid, PhD Institute of Evolutionary Biology and Environmental Studies
Life Sciences - Administration/Government
20.12.2016
Medicine/Pharmacology - Life Sciences
19.12.2016
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases Novartis to broaden liver portfolio to deliver best-in
Medicine/Pharmacology - Life Sciences
16.12.2016
Novartis drug Votubia recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with TSC
If approved, Votubia would be the first adjunctive treatment specifically for refractory seizures in children and adults with tuberous sclerosis complex (TSC)   Seizures are the most common TSC-relat
Medicine/Pharmacology - Life Sciences
16.12.2016
Novartis receives positive CHMP recommendation for Ilaris to treat rare diseases in adults and children called Periodic Fever Syndromes
Periodic Fever Syndromes are rare diseases mostly affecting children and cause recurrent and disabling fevers with potentially life-threatening complications   Ilaris (canakinumab) is recommended for
Medicine/Pharmacology - Life Sciences
15.12.2016
Magnetic forces purify the blood
Magnetic forces purify the blood
Every five seconds, someone in the world dies from blood poisoning. Hemotune, a young start-up founded by ETH researchers, is developing a revolutionary blood purification system to address this problem. Lukas Langenegger picks up a small glass ampoule containing a dark, reddish-brown fluid. Then he holds a magnet against the vial, and iron particles accumulate on the edge of the glass as if by magic, leaving behind a crystal-clear fluid.
Medicine/Pharmacology - Life Sciences
07.12.2016
Roche’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche's Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer Approval based on two large Phase III studies including GOG-0213 that showed a five month overall survival difference for women with platinum-sensitive recurrent ovarian cancer on Avastin plus chemotherapy compared to chemotherapy alone In the United States, Avastin is now approved for nine distinct uses across six different type
Medicine/Pharmacology - Life Sciences
07.12.2016
Novartis’ Lucentis received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions
Novartis' Lucentis received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions The European Commission approved Lucentis to treat patients for vi
Medicine/Pharmacology - Life Sciences
06.12.2016
Novartis announces Zykadia first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC
Patients without brain metastases at diagnosis experienced median progression-free survival of 26.3 months, the longest seen in a global Phase III study in ALK+ NSCLC   Patients with measurable brain metastases in the Zykadia arm experienced an intracranial response rate of more than 70%   Data will be used to support global regulatory submissions for first-line use of Zykadia in ALK+ advanced NSCLC patients - Novartis today announced result
Medicine/Pharmacology - Life Sciences
05.12.2016
New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product
ASSIST-FL trial demonstrates equivalent safety, efficacy, pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar rituximab (GP2013) to the reference product Interim data in over 600 adults show potential of GP2013 as an alternative rituximab Sandoz proposed biosimilar rituximab is the company's first monoclonal antibody candidate Holzkirchen, December 5, 2016 - Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced data from the ASSIST-FL trial.
Medicine/Pharmacology - Life Sciences
05.12.2016
Re-emergence of Syphilis Traced to Pandemic Strain Cluster
Re-emergence of Syphilis Traced to Pandemic Strain Cluster
Syphilis has plagued humankind for over 500 years. After the first reported outbreaks struck Europe in 1495, the disease spread rapidly to other continents and swelled to a global pandemic. When treatment with the antibiotic penicillin became available in the mid-twentieth century, infection rates started to decrease dramatically.
Life Sciences - Medicine/Pharmacology
05.12.2016
Researchers uncover protein-based ‘cancer signature'
Researchers uncover protein-based ‘cancer signature’
A research team at the University of Basel's Biozentrum has investigated the expression of ribosomal proteins in a wide range of human tissues including tumors and discovered a cancer type specific signature. As the researchers report in ‘Genome Biology' this ‘cancer signature' could potentially be used to predict the progression of the disease.
Medicine/Pharmacology - Life Sciences
04.12.2016
Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
82% (41 of 50) of patients achieved complete remission or complete remission with incomplete blood count recovery in interim analysis of Novartis study (ELIANA) ELIANA, the first global CAR T'cell tr
Life Sciences - Media
02.12.2016
Evaluation of scientific rigor in animal research
Media releases, information for representatives of the media Media Relations (E) In the course of the ‘reproducibility crisis' in biomedical research, scientific rigor in animal reserach, and thus the ethical justification of animal experiments, has also been questioned. Commissioned by the Swiss Federal Food Safety and Veterinary Office (FSVO), researchers from the University of Bern have assessed scientific rigor in animal experimentation in Switzerland.
Medicine/Pharmacology - Life Sciences
28.11.2016
Successfully Treating Genetically Determined Autoimmune Enteritis
Using targeted immunotherapy, doctors have succeeded in curing a type of autoimmune enteritis caused by a recently discovered genetic mutation. This report comes from researchers at the Department of Biomedicine of the University of Basel and University Hospital Basel. Their results raise new possibilities for the management of diarrhea, which is often a side effect of melanoma treatment.
Life Sciences - Astronomy
26.11.2016
Discover your brain at planète santé
Discover your brain at planète santé
What does it feel like to recover from brain damage? Have you ever tricked your senses into sensing one thing but experiencing something entirely different? Walk inside a huge inflatable brain and play with optical illusions.
Medicine/Pharmacology - Life Sciences
18.11.2016
Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator
No clinically meaningful differences between biosimilar etanercept and the originator product in safety and efficacy over 52 weeks   Innovative study design demonstrates switching between biosimilar etanercept and the originator product has no impact on safety and efficacy   Sandoz biosimilar etanercept was approved by the FDA* in August 2016 and is currently under review by the EMA ** Holzkirchen, November 18, 2016 - Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced the publication of the EGALITY study in the British Journal of Dermatology .
Medicine/Pharmacology - Life Sciences
17.11.2016
Antibiotic resistance: Swiss physicians, vets, biologists and environmental researchers are working together to find solutions
Antibiotic resistance: Swiss physicians, vets, biologists and environmental researchers are working together to find solutions
The SNSF is launching the National Research Programme "Antimicrobial Resistance", which aims to develop new solutions to ensure that antibiotics remain effective. Worldwide, more and more pathogens are becoming resistant to today's antibiotics. The aim of European Antibiotic Awareness Day on 18 November 2016 is to highlight the fact that medicines are losing their effectiveness as a result and that once easy-to-treat infections are turning into deadly diseases.
1 2 3 4 5 ... 11 Next »